GlassScriptPhysician profile
Fernando N Gamarra
NPI 1457473654
$13,765.80
in general payments reported to CMS, 2019-2025
39 companies · $3,341 in 2025
The $3,341 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $251 · 2021: $1,395 · 2022: $2,151 · 2023: $2,650 · 2024: $2,733 · 2025: $3,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,723.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,467.74 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,699.54 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $1,508.22 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,352.28 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $869.16 | 2019-2025 | |
| Genzyme Corporation | $518.51 | 2022-2025 | |
| Qol Medical, LLC | $504.28 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $503.62 | 2022-2025 | Ibsrela |
| Celgene Corporation | $436.80 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $424.69 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $351.43 | 2019-2025 | Ocaliva |
| Braintree Laboratories, INC. | $337.29 | 2019-2024 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $207.43 | 2021-2025 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $190.25 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $138.19 | 2024-2025 | Omvoh |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $120.67 | 2022-2025 | Injectafer |
| Aimmune Therapeutics, INC. | $113.67 | 2024-2025 | Vowst, Zenpep |
| Merck Sharp & Dohme LLC | $108.46 | 2022-2024 | Dificid |
| Allergan, INC. | $94.41 | 2019-2020 | |
| Vivus LLC | $90.83 | 2024-2025 | Qsymia |
| Nestle Healthcare Nutrition INC. | $76.75 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $74.70 | 2023 | Idacio |
| Celltrion USA INC. | $68.53 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $63.35 | 2021-2025 | |
| Novo Nordisk INC | $55.67 | 2020-2025 | Wegovy |
| Redhill Biopharma INC. | $51.14 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $50.30 | 2024 | Iqirvo |
| Madrigal Pharmaceuticals | $42.83 | 2025 | Rezdiffra |
| Mylan Institutional INC. | $42.65 | 2023 | Hulio |
| Medtronic, INC. | $30.47 | 2021 | |
| Capsovision, INC. | $27.56 | 2023-2024 | Capsocam Plus |
| Organon LLC | $25.04 | 2023 | Hadlima |
| Amgen INC. | $22.12 | 2023 | Avsola |
| Ironwood Pharmaceuticals, INC | $18.75 | 2021 | |
| Shionogi INC | $16.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.51 | 2023 | Cyltezo |
| Echosens North America, INC. | $16.27 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.39 | 2022 | |
| Romark Laboratories, Lc | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Gamarra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.